SELLAS reports Q2 2026 financial results and corporate update
Net loss for Q2 2026 was $9.6M, with cash at $138.3M. Phase 3 REGAL trial event count approaching, SLS009 enrollment at 28 patients.
Latest SELLAS Life Sciences News & Updates
See the latest news and media coverage for SELLAS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Late-stage clinical biopharmaceutical company developing cancer therapies
sellaslifesciences.com- Headquarters
- New York, United States
- Founded year
- 2012
- Company type
- Public company
- Number of employees
- 15–50
- Industry
- Pharmaceuticals
Last updated
Latest news about SELLAS Life Sciences (SELLAS)
In short: SELLAS Life Sciences neared a pivotal Phase 3 REGAL trial readout in AML while reporting narrowed net losses for the second quarter of 2026.
Company announcements
SELLAS reports Q1 2026 financial results and corporate update
Cash position $107.1M, REGAL trial at 78 events, SLS009 Phase 2 dosing ongoing.
SELLAS reports full year 2025 financial results and corporate update
Cash position $71.8M; net loss $26.9M; progress in GPS and SLS009 trials.
SELLAS enrolls first patient in first-line AML trial of SLS009
The randomized Phase 2 study will enroll 80 patients unlikely to benefit from standard therapy.
Media coverage
A Sellas immunotherapy study, long delayed, will end in failure
Sellas Life Sciences Group is a blowup waiting to happen. My prediction: Sellas' experimental immunotherapy will fail to prolong survival compared to standard treatment for...
SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck
ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology...
Legal Probes And Dilution Fears Hammer Sellas Stock - TipRanks.com
SELLAS Life Sciences Group ( ($SLS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement. Sellas Life Sciences Group...
Sellas Life (SLS) Falls 13% as Firm Still Mum on ALM Drug Candidate
Sellas Life Sciences (NASDAQ:SLS) saw its share price decline by 13.15 percent on Friday to close at...
Never miss news about SELLAS
Track SELLAS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
SELLAS competitors & trending companies
Browse news for competitors to SELLAS and other trending companies.
Abcuro
Eikon
Oncopeptides
Anocca
Kestrel
Kura
Alligator
Genmab
Candel
Repertoire
Immutep
Ascelia Pharma
ImmunityBio
Instil Bio
BioLineRx
Compugen
Can-Fite
Aktis Oncology
Solu
Agenus
Replimune
Iovance
Zymeworks
Aprea Therapeutics
Aura Biosciences
Syndax
Oblique Therapeutics
Allarity
Active Biotech
Sprint Bioscience
BioInvent
Qarlbo
Wellfound
EMA
FDA
Talentful